Management of Intracranial Fibromuscular Dysplasia in a 30-Year-Old Patient
For a 30-year-old patient with intracranial fibromuscular dysplasia (FMD) identified on CT, initiate lifelong antiplatelet therapy (aspirin) and perform one-time comprehensive vascular imaging from brain-to-pelvis to detect multivessel involvement, aneurysms, and dissections.
Immediate Diagnostic Workup
Complete a one-time head-to-pelvis vascular screening using CT angiography (CTA) or MR angiography (MRA) 1, 2, 3. This recommendation is strongly supported by registry data showing:
- Multivessel involvement occurs in 43.5%-66.3% of FMD patients
- Intracranial aneurysms are present in 7%-30.6% of cases
- Arterial dissections occur in 5.6%-28.1% of patients 1, 2
The high prevalence of these potentially life-threatening vascular manifestations—and their associated morbidity requiring possible endovascular or surgical intervention—makes comprehensive screening essential 1.
Imaging Modality Selection
For intracranial evaluation, CTA is preferred over conventional angiography for initial assessment 4. While catheter angiography remains the reference standard, it is invasive and reserved for:
- Further characterization of vascular malformations suggested by noninvasive testing
- Pre-procedural planning if intervention is contemplated
- Cases where CTA/MRA are negative but clinical suspicion remains high 4
Important caveat: Catheter angiography may miss vascular lesions in the acute period that become apparent on repeat imaging several weeks later 4.
Medical Management
Antiplatelet Therapy
Initiate antiplatelet therapy with aspirin 5, 6, 2, 3, 7. Registry data shows antiplatelet agents are prescribed in up to 72.9% of FMD patients, with aspirin specifically used in up to 70.2% 1. The rationale is prevention of thromboembolic complications, particularly given the association with stroke and TIA (occurring in 7%-10% and 5%-12% of patients, respectively) 2.
Critical nuance: While consensus recommendations support lifelong antiplatelet therapy 2, 3, the evidence is somewhat uncertain as beneficial effects have not been demonstrated specifically in FMD patients through controlled trials 1. However, given the low risk of aspirin therapy and the high stakes of cerebrovascular events in this young patient, antiplatelet therapy is reasonable and widely recommended 5, 6, 2.
Blood Pressure Management
Achieve strict blood pressure control if hypertension is present 3. More than two-thirds of cerebrovascular FMD patients have hypertension 6. Target aggressive blood pressure management as part of stroke risk modification.
Statins
Do not routinely prescribe statins for FMD, as this is a non-atherosclerotic arteriopathy 3. Statins are not indicated unless there are separate atherosclerotic risk factors.
Lifestyle Modifications
- Mandatory smoking cessation if applicable—approximately 50% of FMD patients have tobacco use history 6, 3
- Encourage regular physical activity but avoid high-risk activities that may predispose to arterial dissection (e.g., contact sports, extreme neck manipulation, high-intensity weightlifting) 3
- Counsel regarding migraine management if present, balancing efficacy with vascular safety 3
Surveillance Strategy
Based on the Massachusetts General Hospital cohort of 81 cerebrovascular FMD patients, the rate of disease progression is relatively low (7 of 67 patients had progressive disease during follow-up, with only 1 cerebrovascular event) 6. This supports conservative management with:
- Surveillance imaging at intervals determined by initial findings (presence of aneurysms, dissections, or high-grade stenosis)
- Clinical monitoring for new symptoms: headaches, pulsatile tinnitus, neurological deficits, or TIA symptoms 2, 3
Endovascular Intervention Considerations
Reserve endovascular treatment for specific indications 2:
- Intracranial aneurysms with risk factors for rupture
- Recurrent ischemic events despite optimal medical management
- Hemodynamically significant stenosis with recurrent symptoms
Angioplasty alone is preferred over stenting when intervention is necessary 8.
Family Screening
Consider selective evaluation of first-degree relatives, particularly female relatives, though routine genetic screening is not currently recommended 3. FMD has familial clustering but specific genetic markers for routine clinical use are not established.
Multidisciplinary Care
Establish care with a multidisciplinary team including neurology, vascular medicine, and interventional specialists given the systemic nature of FMD and its protean manifestations 9, 8, 3. Patient education and participation in FMD registries can advance knowledge and improve outcomes 3.